Bellerophon Therapeutics Current Valuation vs. Cash Per Share

BLPHDelisted Stock  USD 0.71  0.01  1.43%   
Based on Bellerophon Therapeutics' profitability indicators, Bellerophon Therapeutics may not be well positioned to generate adequate gross income at this time. It has a very high probability of underperforming in December. Profitability indicators assess Bellerophon Therapeutics' ability to earn profits and add value for shareholders.
For Bellerophon Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Bellerophon Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Bellerophon Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Bellerophon Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Bellerophon Therapeutics over time as well as its relative position and ranking within its peers.
  
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.
Please note, there is a significant difference between Bellerophon Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Bellerophon Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bellerophon Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Bellerophon Therapeutics Cash Per Share vs. Current Valuation Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Bellerophon Therapeutics's current stock value. Our valuation model uses many indicators to compare Bellerophon Therapeutics value to that of its competitors to determine the firm's financial worth.
Bellerophon Therapeutics is rated below average in current valuation category among its peers. It is rated below average in cash per share category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Bellerophon Therapeutics by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Bellerophon Therapeutics' Pink Sheet. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.

Bellerophon Current Valuation vs. Competition

Bellerophon Therapeutics is rated below average in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Health Care industry is currently estimated at about 1.01 Billion. Bellerophon Therapeutics has negative current valuation of (9.32 Million) contributing less than 1% to the industry.

Bellerophon Cash Per Share vs. Current Valuation

Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.

Bellerophon Therapeutics

Enterprise Value

 = 

Market Cap + Debt

-

Cash

 = 
(9.32 M)
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
Cash per Share is a ratio of current cash on hands or in the banks of the company to a total number of shares outstanding. It is used to determine a firm's liquidity and is a good indicator of the overall financial health of a company. Value investors often compare this ratio to the current stock quote, and if it exceeds the stock price they would invest in it.

Bellerophon Therapeutics

Cash Per Share

 = 

Total Cash

Average Shares

 = 
1.71 X
Companies with high Cash per Share ratio will be considered as an attractive investment by most investors. In most industries if you can single out an equity instrument trading below its cash per share value, you have a bargain and should consider buying it. Finding the stocks traded below their cash value, therefore, can be a good starting point for investors using strategies based on fundamentals.

Bellerophon Cash Per Share Comparison

Bellerophon Therapeutics is currently under evaluation in cash per share category among its peers.

Bellerophon Therapeutics Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Bellerophon Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Bellerophon Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Bellerophon Therapeutics' change in net profit over the period of time. It can combine multiple indicators of Bellerophon Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Bellerophon Therapeutics, Inc. was founded in 2009 and is headquartered in Warren, New Jersey. Bellerophon Ther operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 20 people.

Bellerophon Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Bellerophon Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Bellerophon Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Bellerophon Therapeutics' important profitability drivers and their relationship over time.

Learn to be your own money manager

Our tools can tell you how much better you can do entering a position in Bellerophon Therapeutics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Idea Analyzer Now

   

Idea Analyzer

Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
All  Next Launch Module

Use Investing Themes to Complement your Bellerophon Therapeutics position

In addition to having Bellerophon Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Cancer Fighters Thematic Idea Now

Cancer Fighters
Cancer Fighters Theme
Biotech and medical diagnostic companies that work on researching drugs or manufacturing of medical and therapeutics equipment that is directly related to the research, treatment, and detection of cancer or cancer related diseases. The Cancer Fighters theme has 60 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Cancer Fighters Theme or any other thematic opportunities.
View All  Next Launch
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.
You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.

Other Consideration for investing in Bellerophon Pink Sheet

If you are still planning to invest in Bellerophon Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Bellerophon Therapeutics' history and understand the potential risks before investing.
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Transaction History
View history of all your transactions and understand their impact on performance
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
FinTech Suite
Use AI to screen and filter profitable investment opportunities